Exenatide : effect of injection time on postprandial glucose in patients with Type 2 diabetesLINNEBJERG, H; KOTHARE, P. A; SKRIVANEK, Z et al.Diabetic medicine. 2006, Vol 23, Num 3, pp 240-245, issn 0742-3071, 6 p.Article

Exenatide : A new option for the treatment of type 2 diabetesBONG KYU YOO; TRILLER, Darren Michael; DONG JOO YOO et al.The Annals of pharmacotherapy. 2006, Vol 40, Num 10, pp 1777-1784, issn 1060-0280, 8 p.Article

The effect of exenatide re-exposure on safety and efficacyFALUDI, Peter; BRODOWS, Robert; BURGER, Jude et al.Peptides (New York, NY. 1980). 2009, Vol 30, Num 9, pp 1771-1774, issn 0196-9781, 4 p.Article

Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanismMING HAO; KUANG, Hong-Yu; ZHENG FU et al.Neurochemistry international. 2012, Vol 61, Num 1, pp 1-6, issn 0197-0186, 6 p.Article

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in miceTREVASKIS, James L; GRIFFIN, Peter S; WITTMER, Carrie et al.American journal of physiology. Gastrointestinal and liver physiology. 2012, Vol 65, Num 4, issn 0193-1857, G762-G772Article

Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activityNIAN GONG; MA, Ai-Niu; ZHANG, Li-Jie et al.British journal of pharmacology. 2011, Vol 163, Num 2, pp 399-412, issn 0007-1188, 14 p.Article

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)CALARA, Federico; TAYLOR, Kristin; HAN, Jenny et al.Clinical therapeutics. 2005, Vol 27, Num 2, pp 210-215, issn 0149-2918, 6 p.Article

Exenatide : An incretin mimetic for the treatment of type 2 diabetes mellitusILTZ, Jason L; BAKER, Danial E; SETTER, Stephen M et al.Clinical therapeutics. 2006, Vol 28, Num 5, pp 652-665, issn 0149-2918, 14 p.Article

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)HILES, Richard A; BAWDON, Roger E; PETRELLA, Ezio M et al.Human & experimental toxicology. 2003, Vol 22, Num 12, pp 623-628, issn 0960-3271, 6 p.Article

Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemiaJIZI JIN; KANG, Hye-Min; JUNYANG JUNG et al.Neuroreport (Oxford). 2014, Vol 25, Num 1, pp 65-70, issn 0959-4965, 6 p.Article

Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivoXUEMIN ZHENG; YING LI; GANG FU et al.Peptides (New York, NY. 1980). 2011, Vol 32, Num 5, pp 964-970, issn 0196-9781, 7 p.Article

GLP-1 based therapy for type 2 diabetesARULMOZHI, D. K; PORTHA, B.European journal of pharmaceutical sciences. 2006, Vol 28, Num 1-2, pp 96-108, issn 0928-0987, 13 p.Article

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesFINEMAN, Mark S; SHEN, Larry Z; TAYLOR, Kristin et al.Diabetes/metabolism research and reviews (Print). 2004, Vol 20, Num 5, pp 411-417, issn 1520-7552, 7 p.Article

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk ReductionLORBER, Daniel.Cardiovascular therapeutics (Print). 2013, Vol 31, Num 4, pp 238-249, issn 1755-5914, 12 p.Article

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metforminRIDDLE, Matthew C; HENRY, Robert R; POON, Terri H et al.Diabetes/metabolism research and reviews (Print). 2006, Vol 22, Num 6, pp 483-491, issn 1520-7552, 9 p.Article

Exenatide in type 2 diabetes : treatment effects in clinical studies and animal study dataGALLWITZ, B.International journal of clinical practice (Esher). 2006, Vol 60, Num 12, pp 1654-1661, issn 1368-5031, 8 p.Article

Exendin-4 decreases amphetamine-induced locomotor activityERREGER, Kevin; DAVIS, Adeola R; POE, Amanda M et al.Physiology & behavior. 2012, Vol 106, Num 4, pp 574-578, issn 0031-9384, 5 p.Article

Incretin mimetics as emerging treatments for type 2 diabetesJOY, Scott V; RODGERS, Philip T; SCATES, Ann C et al.The Annals of pharmacotherapy. 2005, Vol 39, Num 1, pp 110-118, issn 1060-0280, 9 p.Article

Exénatide pour traiter le diabète de type 2 = Exenatide for type 2 diabetesThe Medical letter on drugs and therapeutics (Edition française). 2005, Vol 27, Num 14, pp 71-72, issn 0253-8512, 2 p.Article

Effects of Exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesBUSE, John B; HENRY, Robert R; HAN, Jenny et al.Diabetes care. 2004, Vol 27, Num 11, pp 2628-2635, issn 0149-5992, 8 p.Article

Extending the Reach of Exendin-4: New Pathways in the Control of Body Weight and Glucose HomeostasisGOOD, Deborah J.Endocrinology (Philadelphia). 2012, Vol 153, Num 5, pp 2051-2053, issn 0013-7227, 3 p.Article

GLP-1 and exendin-4 can reverse hyperlipidic-related osteopeniaNUCHE-BERENGUER, Bernardo; LOZANO, Daniel; GUTIERREZ-ROJAS, Irene et al.Journal of endocrinology. 2011, Vol 209, Num 2, pp 203-210, issn 0022-0795, 8 p.Article

Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4KANOSKI, Scott E; FORTIN, Samantha M; ARNOLD, Myrtha et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3103-3112, issn 0013-7227, 10 p.Article

GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and HumansGIL-LOZANO, Manuel; PEREZ-TILVE, Diego; ALVAREZ-CRESPO, Mayte et al.Endocrinology (Philadelphia). 2010, Vol 151, Num 6, pp 2629-2640, issn 0013-7227, 12 p.Article

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosisMARZIONI, M; ALPINI, G; SACCOMANNO, S et al.Gut. 2009, Vol 58, Num 7, pp 990-997, issn 0017-5749, 8 p.Article